IMpower133: Finally Moving the Needle in SCLC

Dr. Jamie E. Chaft Discusses Emerging Data on Induction Immunotherapy for NSCLC

Ongoing Clinical Challenges: Defining Immunotherapy Benefit for Patients With NSCLC and Poor Performance Status

Explaining IMpower132: An Interview with Dr. Vassiliki A. Papadimitrakopoulou

Targeted Therapy Plus Immune Checkpoint Inhibitors: Research Opportunities, But No Improvement in Activity to Date

Neoadjuvant Nivolumab Shows Unprecedented Pathologic Complete Response for Stage III NSCLC

KEYNOTE-042: No Hard and Fast Rules for First-Line Pembrolizumab Regarding PD-L1–Positive Disease

Updated Results from the Phase III ALEX Trial: Embracing Hazard Ratios

Immunotherapy Succeeds in Squamous NSCLC, Establishing a New Frontline Standard of Care

AACR 2018: First-Line Management of Advanced NSCLC Enters New Era

PD-L1 IHC Blueprint Project: Ongoing Progress Toward Consistency Among Assays

PACIFIC Trial Leads to Durvalumab Approval in United States